title: The EUTOS score identifies chronic myeloid leukeamia patients with poor prognosis treated with imatinib first or second line.
authors: Massimo
authors: M
authors: Breccia
authors: Paola
authors: P
authors: Finsinger
authors: Giuseppina
authors: G
authors: Loglisci
authors: Roberto
authors: R
authors: Latagliata
authors: Marco
authors: M
authors: Mancini
authors: Adriano
authors: A
authors: Salaroli
authors: Alessandra
authors: A
authors: Serrao
authors: Irene
authors: I
authors: Zacheo
authors: Giuliana
authors: G
authors: Alimena
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D017024:Chemotherapy, Adjuvant; D019937:Diagnostic Techniques and Procedures; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D010879:Piperazines / Q000627:therapeutic use*; D011237:Predictive Value of Tests; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use*; D012107:Research Design; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate